Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy

Cheng Kuo Lai, Yu Luen Lu, Jer Tsong Hsieh, Shih Chang Tsai, Chun Lung Feng, Yuh Shyan Tsai, Pei Ching Tsai, Hong Lin Su, Yu Hsin Lin, Chih Ho Lai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: The aim of this work was to develop pH-responsive nanoparticles encapsulating CdtB and to demonstrate that these particles represent a potential therapeutic agent for gastric cancer. Materials & methods: Chitosan/heparin nanoparticle-encapsulated CdtB was prepared and the delivery efficiency was monitored by confocal laser scanning microscopy. The molecular basis of the nanoparticle-encapsulated CdtB-mediated p53 activation pathway was explored by immunoblot analysis. Antitumoral activities were investigated by analyzing the cell cycle and apoptosis. Results: Chitosan/heparin nanoparticle-encapsulated CdtB preferentially inhibited the proliferation of cells derived from gastric cancer, but not in primary gastric epithelial cells. Treatment of cells with nanoparticle-encapsulated CdtB enhanced cell-cycle arrest at G2/M, followed by apoptosis. Moreover, our data showed that the mechanism for nanoparticle- encapsulated CdtB-induced cell death was mediated by ATM-dependent DNA damage checkpoint responses. Conclusion: These findings indicate that chitosan/heparin nanoparticle-encapsulated CdtB could represent a new CdtB delivery strategy for the treatment of gastric cancer. Original submitted 8 May 2012; Revised submitted 5 February 201.

Original languageEnglish (US)
Pages (from-to)803-817
Number of pages15
JournalNanomedicine
Volume9
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Chitosan
Nanoparticles
toxin
Stomach Neoplasms
Heparin
cancer
Cell death
Cells
apoptosis
proliferation
activation
damages
Therapeutics
death
efficiency
G2 Phase Cell Cycle Checkpoints
Apoptosis
Gastrointestinal Agents
airborne thematic mapper
Automatic teller machines

Keywords

  • apoptosis
  • cell cycle
  • chitosan
  • cytolethal distending toxin
  • heparin
  • nanoparticle

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development
  • Medicine(all)

Cite this

Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. / Lai, Cheng Kuo; Lu, Yu Luen; Hsieh, Jer Tsong; Tsai, Shih Chang; Feng, Chun Lung; Tsai, Yuh Shyan; Tsai, Pei Ching; Su, Hong Lin; Lin, Yu Hsin; Lai, Chih Ho.

In: Nanomedicine, Vol. 9, No. 6, 2014, p. 803-817.

Research output: Contribution to journalArticle

Lai, CK, Lu, YL, Hsieh, JT, Tsai, SC, Feng, CL, Tsai, YS, Tsai, PC, Su, HL, Lin, YH & Lai, CH 2014, 'Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy', Nanomedicine, vol. 9, no. 6, pp. 803-817. https://doi.org/10.2217/nnm.13.54
Lai, Cheng Kuo ; Lu, Yu Luen ; Hsieh, Jer Tsong ; Tsai, Shih Chang ; Feng, Chun Lung ; Tsai, Yuh Shyan ; Tsai, Pei Ching ; Su, Hong Lin ; Lin, Yu Hsin ; Lai, Chih Ho. / Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. In: Nanomedicine. 2014 ; Vol. 9, No. 6. pp. 803-817.
@article{9670dd189c334ed786befeef3de2960b,
title = "Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy",
abstract = "Aim: The aim of this work was to develop pH-responsive nanoparticles encapsulating CdtB and to demonstrate that these particles represent a potential therapeutic agent for gastric cancer. Materials & methods: Chitosan/heparin nanoparticle-encapsulated CdtB was prepared and the delivery efficiency was monitored by confocal laser scanning microscopy. The molecular basis of the nanoparticle-encapsulated CdtB-mediated p53 activation pathway was explored by immunoblot analysis. Antitumoral activities were investigated by analyzing the cell cycle and apoptosis. Results: Chitosan/heparin nanoparticle-encapsulated CdtB preferentially inhibited the proliferation of cells derived from gastric cancer, but not in primary gastric epithelial cells. Treatment of cells with nanoparticle-encapsulated CdtB enhanced cell-cycle arrest at G2/M, followed by apoptosis. Moreover, our data showed that the mechanism for nanoparticle- encapsulated CdtB-induced cell death was mediated by ATM-dependent DNA damage checkpoint responses. Conclusion: These findings indicate that chitosan/heparin nanoparticle-encapsulated CdtB could represent a new CdtB delivery strategy for the treatment of gastric cancer. Original submitted 8 May 2012; Revised submitted 5 February 201.",
keywords = "apoptosis, cell cycle, chitosan, cytolethal distending toxin, heparin, nanoparticle",
author = "Lai, {Cheng Kuo} and Lu, {Yu Luen} and Hsieh, {Jer Tsong} and Tsai, {Shih Chang} and Feng, {Chun Lung} and Tsai, {Yuh Shyan} and Tsai, {Pei Ching} and Su, {Hong Lin} and Lin, {Yu Hsin} and Lai, {Chih Ho}",
year = "2014",
doi = "10.2217/nnm.13.54",
language = "English (US)",
volume = "9",
pages = "803--817",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy

AU - Lai, Cheng Kuo

AU - Lu, Yu Luen

AU - Hsieh, Jer Tsong

AU - Tsai, Shih Chang

AU - Feng, Chun Lung

AU - Tsai, Yuh Shyan

AU - Tsai, Pei Ching

AU - Su, Hong Lin

AU - Lin, Yu Hsin

AU - Lai, Chih Ho

PY - 2014

Y1 - 2014

N2 - Aim: The aim of this work was to develop pH-responsive nanoparticles encapsulating CdtB and to demonstrate that these particles represent a potential therapeutic agent for gastric cancer. Materials & methods: Chitosan/heparin nanoparticle-encapsulated CdtB was prepared and the delivery efficiency was monitored by confocal laser scanning microscopy. The molecular basis of the nanoparticle-encapsulated CdtB-mediated p53 activation pathway was explored by immunoblot analysis. Antitumoral activities were investigated by analyzing the cell cycle and apoptosis. Results: Chitosan/heparin nanoparticle-encapsulated CdtB preferentially inhibited the proliferation of cells derived from gastric cancer, but not in primary gastric epithelial cells. Treatment of cells with nanoparticle-encapsulated CdtB enhanced cell-cycle arrest at G2/M, followed by apoptosis. Moreover, our data showed that the mechanism for nanoparticle- encapsulated CdtB-induced cell death was mediated by ATM-dependent DNA damage checkpoint responses. Conclusion: These findings indicate that chitosan/heparin nanoparticle-encapsulated CdtB could represent a new CdtB delivery strategy for the treatment of gastric cancer. Original submitted 8 May 2012; Revised submitted 5 February 201.

AB - Aim: The aim of this work was to develop pH-responsive nanoparticles encapsulating CdtB and to demonstrate that these particles represent a potential therapeutic agent for gastric cancer. Materials & methods: Chitosan/heparin nanoparticle-encapsulated CdtB was prepared and the delivery efficiency was monitored by confocal laser scanning microscopy. The molecular basis of the nanoparticle-encapsulated CdtB-mediated p53 activation pathway was explored by immunoblot analysis. Antitumoral activities were investigated by analyzing the cell cycle and apoptosis. Results: Chitosan/heparin nanoparticle-encapsulated CdtB preferentially inhibited the proliferation of cells derived from gastric cancer, but not in primary gastric epithelial cells. Treatment of cells with nanoparticle-encapsulated CdtB enhanced cell-cycle arrest at G2/M, followed by apoptosis. Moreover, our data showed that the mechanism for nanoparticle- encapsulated CdtB-induced cell death was mediated by ATM-dependent DNA damage checkpoint responses. Conclusion: These findings indicate that chitosan/heparin nanoparticle-encapsulated CdtB could represent a new CdtB delivery strategy for the treatment of gastric cancer. Original submitted 8 May 2012; Revised submitted 5 February 201.

KW - apoptosis

KW - cell cycle

KW - chitosan

KW - cytolethal distending toxin

KW - heparin

KW - nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84903759015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903759015&partnerID=8YFLogxK

U2 - 10.2217/nnm.13.54

DO - 10.2217/nnm.13.54

M3 - Article

C2 - 24024568

AN - SCOPUS:84903759015

VL - 9

SP - 803

EP - 817

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 6

ER -